Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:6354
Name chronic lymphocytic leukemia/small lymphocytic lymphoma
Definition A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant Ibrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Ibrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Rituximab + Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Rituximab + Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Idelalisib + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Idelalisib + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss N/A chronic lymphocytic leukemia/small lymphocytic lymphoma not applicable detail...
TP53 mutant N/A chronic lymphocytic leukemia/small lymphocytic lymphoma not applicable detail...
TP53 loss Obinutuzumab + Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Obinutuzumab + Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Acalabrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Acalabrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Duvelisib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Duvelisib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Zanubrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma predicted - sensitive detail...
TP53 loss Acalabrutinib + Obinutuzumab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Acalabrutinib + Obinutuzumab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Alemtuzumab + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Alemtuzumab + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Methylprednisolone + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Methylprednisolone + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Obinutuzumab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Obinutuzumab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Idelalisib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Idelalisib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Lenalidomide + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Lenalidomide + Rituximab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Zanubrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Pirtobrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Pirtobrutinib chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Methylprednisolone + Obinutuzumab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Methylprednisolone + Obinutuzumab chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 loss Ibrutinib + Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
TP53 mutant Ibrutinib + Venetoclax chronic lymphocytic leukemia/small lymphocytic lymphoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT01125176 Phase II Lenalidomide + Rituximab + Thalidomide Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL Completed USA 0
NCT01253460 Phase II Cyclophosphamide Rituximab + Sapacitabine Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Terminated USA 0
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA | FRA | ESP | DEU 0
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 14
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 20
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01886859 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed USA 0
NCT01976585 Phase Ib/II CDX-301 + Poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Completed USA 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | GBR | ESP 0
NCT02005289 Phase II Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Active, not recruiting USA 0
NCT02006485 Phase I Ublituximab + Umbralisib Ibrutinib Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies Completed USA 0
NCT02007044 Phase II Ibrutinib Ibrutinib + Rituximab Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02029443 Phase Ib/II Acalabrutinib ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting USA | ITA | GBR 0
NCT02160015 Phase I Ibrutinib + Lenalidomide + Rituximab Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02254772 Phase Ib/II Ipilimumab + SD-101 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Completed USA 0
NCT02266147 Phase Ib/II SD-101 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Terminated USA 0
NCT02296918 Phase I Acalabrutinib + Obinutuzumab ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL Active, not recruiting USA 0
NCT02329847 Phase Ib/II Ibrutinib + Nivolumab Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies Completed USA | ESP | AUS 3
NCT02337829 Phase II Acalabrutinib ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Active, not recruiting USA 0
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02381080 Phase I Erythromycin + Ibrutinib + Voriconazole Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Completed ESP | CAN 1
NCT02384954 Phase Ib/II ALT-803 + Rituximab ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab Terminated USA 0
NCT02406742 Phase Ib/II Obinutuzumab Rituximab Ibrutinib CC-122 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE) Completed USA | ITA | ESP | DEU | AUT 0
NCT02420912 Phase II Ibrutinib + Nivolumab Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Completed USA 0
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA | GBR | FRA 0
NCT02514083 Phase II Fludarabine + Ibrutinib A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL Active, not recruiting USA 0
NCT02518555 Phase II Ibrutinib Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting USA 0
NCT02529813 Phase I Cyclophosphamide + Fludarabine + Tisagenlecleucel CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Completed USA 0
NCT02556931 Phase II Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed USA 0
NCT02576275 Phase III Bendamustine + Rituximab Duvelisib A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Withdrawn USA 0
NCT02614508 Phase I Buparlisib + Ibrutinib Buparlisib + Ofatumumab Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Terminated USA 0
NCT02626455 Phase III Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 26
NCT02629809 Phase II Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02639910 Phase II Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) Completed USA | ITA | GBR | DEU | AUT 1
NCT02640209 Phase I CART19 cells Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) Terminated USA 0
NCT02640833 Phase I Duvelisib + Venetoclax A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor Withdrawn USA 0
NCT02662296 Phase II Idelalisib Ibrutinib Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Withdrawn USA 0
NCT02677948 Phase Ib/II Ibrutinib + Pacritinib Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Withdrawn USA 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02756897 Phase II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA 0
NCT02787369 Phase I Idelalisib + Ricolinostat Ibrutinib + Ricolinostat ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL Active, not recruiting USA 0
NCT02825836 Phase Ib/II TL-895 Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma Active, not recruiting USA | ITA | GBR 4
NCT02846623 Phase II Atezolizumab + Obinutuzumab + Venetoclax Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Recruiting USA 0
NCT02867618 Phase Ib/II Carfilzomib + Umbralisib Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma Terminated USA 0
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Completed USA 0
NCT02910583 Phase II Ibrutinib Ibrutinib + Venetoclax Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Unknown status USA | NZL | ITA | ESP | AUS 1
NCT02914938 Phase I zandelisib Rituximab + zandelisib A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Terminated USA 1
NCT02924402 Phase I XmAb13676 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Active, not recruiting USA | GBR | FRA 1
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT02966756 Phase II Venetoclax A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NZL | AUS 2
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Completed USA 0
NCT03088878 Phase Ib/II Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Active, not recruiting USA 0
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03204188 Phase II Fludarabine + Ibrutinib + Pembrolizumab Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting USA 0
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Terminated USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed NLD | GBR | DEU 0
NCT03331198 Phase Ib/II Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Active, not recruiting USA 0
NCT03336333 Phase III Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | BEL | AUT | AUS 6
NCT03370185 Phase II Duvelisib Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Withdrawn USA 0
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated USA 0
NCT03406156 Phase III Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Completed USA 0
NCT03422393 Phase I Ibrutinib + Venetoclax Venetoclax Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib Active, not recruiting USA 0
NCT03454165 Phase I BNC105P + Ibrutinib A Study of BNC105P Combined With Ibrutinib Completed USA 0
NCT03462719 Phase III Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) Active, not recruiting USA | NLD | GBR | FRA | ESP | CAN | BEL 7
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03492125 Phase I MS-553 A Study Of The Selective PKC-beta Inhibitor MS- 553 Recruiting USA 0
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Active, not recruiting USA 0
NCT03516617 Phase II Acalabrutinib Acalabrutinib + Obinutuzumab Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting USA 0
NCT03534323 Phase Ib/II Duvelisib + Venetoclax Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL Recruiting USA 0
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting USA 0
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Recruiting USA | AUS 0
NCT03572634 Phase Ib/II Dubermatinib Dubermatinib + Ibrutinib Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Terminated USA 0
NCT03579888 Phase I CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine CD19-Specific T Cells Post AlloSCT Terminated USA 0
NCT03580928 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) Active, not recruiting USA 0
NCT03625037 Phase Ib/II Epcoritamab-bysp First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 6
NCT03701282 Phase III Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia Active, not recruiting USA 1
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Completed USA | AUS 0
NCT03734016 Phase III Ibrutinib Zanubrutinib A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Active, not recruiting 1
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Active, not recruiting USA | ITA | GBR | FRA | AUS 5
NCT03759184 Phase I Obinutuzumab + rhIL-15 Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia Terminated USA 0
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Active, not recruiting USA | ITA | FRA | ESP 3
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Active, not recruiting USA | ITA | FRA | ESP 2
NCT03788291 Phase II Acalabrutinib + Rituximab Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Active, not recruiting USA 0
NCT03824483 Phase II Obinutuzumab + Venetoclax + Zanubrutinib Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Recruiting USA 0
NCT03828448 Phase II Ublituximab + Umbralisib Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma Terminated USA 0
NCT03884972 Phase I Trabectedin + Venetoclax Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Withdrawn USA 0
NCT03893682 Phase I CG-806 A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Active, not recruiting USA 0
NCT03960840 Phase I Ibrutinib + YTB323 YTB323 CD19-specific CAR-T Cells in CLL/SLL and DLBCL Recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT03961672 Phase II Duvelisib Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting USA 0
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04014205 Phase I Orelabrutinib A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies Active, not recruiting USA 3
NCT04018248 Phase I BR101801 BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) Active, not recruiting USA 1
NCT04038359 Phase II Duvelisib A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) Completed USA | ITA | GBR | DEU 4
NCT04072458 Phase I BP1002 A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Recruiting USA 0
NCT04116437 Phase II Zanubrutinib A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib Recruiting USA 0
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Completed USA 0
NCT04155840 Phase II Bendamustine + Copanlisib + Rituximab Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Terminated USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04169737 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting USA 0
NCT04209621 Phase II Duvelisib + Ibrutinib Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Terminated USA 0
NCT04230304 Phase II Daratumumab + Ibrutinib Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Active, not recruiting USA 0
NCT04269902 Phase III Obinutuzumab + Venetoclax Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study Recruiting USA | CAN 0
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | NZL | ITA | GBR | ESP | DEU | AUS 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Active, not recruiting USA | ESP 3
NCT04419519 Phase II Venetoclax Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Recruiting USA 0
NCT04434196 Phase I CC-99282 + Obinutuzumab A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting USA | ESP | CAN | AUT 0
NCT04458610 Phase II Rituximab + Zanubrutinib BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient Recruiting USA 0
NCT04501939 Phase II Cirmtuzumab + Venetoclax Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax) Active, not recruiting USA 0
NCT04505254 Phase II Acalabrutinib + Obinutuzumab Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA | GBR | FRA | ESP | AUS 3
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04560322 Phase II Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab + Venetoclax Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL Recruiting USA 0
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Active, not recruiting USA 0
NCT04588922 Phase I GFH009 A Study of GFH009 in Patients With Hematologic Malignancies Recruiting USA 1
NCT04623541 Phase Ib/II Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 3
NCT04624633 Phase II Acalabrutinib + Ublituximab + Umbralisib AU2 In Relapsed and Untreated CLL Active, not recruiting USA 0
NCT04657094 Phase II Acalabrutinib Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT04659044 Phase II Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting USA 0
NCT04660045 Phase II Acalabrutinib Early Intervention With Acalabrutinib in Patients With High Risk CLL Withdrawn USA 0
NCT04665115 Phase II Ibrutinib Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Withdrawn USA 0
NCT04666038 Phase III Idelalisib + Rituximab Pirtobrutinib Bendamustine + Rituximab Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT04685915 Phase II Copanlisib + Ibrutinib Copanlisib Plus Ibrutinib in R/R CLL Withdrawn 0
NCT04704323 Phase I CAP-100 CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting USA | ESP 0
NCT04722172 Phase II Acalabrutinib + Obinutuzumab A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL Active, not recruiting USA 0
NCT04728893 Phase II ARQ 531 Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT04758975 Phase II Rituximab + Venetoclax Ibrutinib + Rituximab + Venetoclax Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE) Recruiting ITA 0
NCT04763083 Phase Ib/II NVG-111 First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma Recruiting GBR 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04775745 Phase I LP-168 Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Recruiting USA 0
NCT04781855 Phase I Ibrutinib + Ipilimumab Ibrutinib + Ipilimumab + Nivolumab Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Active, not recruiting USA 0
NCT04809467 Phase Ib/II Parsaclisib + Tafasitamab-cxix A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 0
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Active, not recruiting USA 0
NCT04843904 Phase I Obinutuzumab + Rituximab + Venetoclax Safe Accelerated Venetoclax Escalation in CLL (SAVE) Recruiting USA 0
NCT04853329 Phase Ib/II CPO107 Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma Suspended USA 0
NCT04861779 Phase I HSK29116 A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting AUS 1
NCT04908228 Phase II Ibrutinib + Obinutuzumab Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL (FIGHT) Recruiting ITA 0
NCT04941716 Phase II Acalabrutinib + Venetoclax Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting USA 0
NCT04965493 Phase III Rituximab + Venetoclax Pirtobrutinib + Rituximab + Venetoclax A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT04981912 Phase I Methylprednisolone + Rituximab Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients Active, not recruiting USA 0
NCT05003141 Phase I PSB202 PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Unknown status USA | AUS 1
NCT05006716 Phase I BGB-16673 A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 3
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05023980 Phase III Pirtobrutinib Bendamustine + Rituximab A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) Recruiting USA | NZL | ITA | GBR | FRA | ESP | AUT | AUS 13
NCT05057494 Phase III Obinutuzumab + Venetoclax Acalabrutinib + Venetoclax A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC) Recruiting USA | FRA | ESP | AUS 3
NCT05069051 Phase II Belimumab + Rituximab + Venetoclax Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR) Recruiting DEU 0
NCT05131022 Phase I NX-5948 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA | NLD | GBR 0
NCT05144347 Phase I XL114 Study of XL114 in Subjects With Non-Hodgkin's Lymphoma Terminated USA 0
NCT05153330 Phase I BMF-219 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations Recruiting USA | NLD | ITA | ESP 1
NCT05168930 Phase II Venetoclax + Zanubrutinib Zanubrutinib and Venetoclax in CLL (ZANU-VEN) Recruiting USA 0
NCT05172700 Expanded access Pirtobrutinib Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer Available 0
NCT05197192 Phase III Obinutuzumab + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk Chronic Lymphatic Leukemia Recruiting DEU 0
NCT05244070 Phase I BMS-986403 + Cytarabine + Fludarabine A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Terminated USA | ESP 0
NCT05254743 Phase III Ibrutinib Pirtobrutinib A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT05256641 Phase Ib/II Acalabrutinib Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Recruiting USA 0
NCT05275504 Phase I TT-01488 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Recruiting USA 0
NCT05336812 Phase II Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia Recruiting USA 0
NCT05360238 Phase Ib/II MB-106 Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL Recruiting USA 0
NCT05388006 Phase II Acalabrutinib + Durvalumab + Venetoclax Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting USA 0
NCT05405309 Phase Ib/II Olaparib + RP-3500 RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) Recruiting USA 0
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | AUS 3
NCT05536349 Phase II Obinutuzumab + Pirtobrutinib + Venetoclax Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) Recruiting USA 0
NCT05602363 Phase I AS-1763 AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma Recruiting USA 0
NCT05624554 Phase III Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab ARQ 531 A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Recruiting USA | AUS 16
NCT05650723 Phase II Venetoclax + Zanubrutinib Obinutuzumab + Venetoclax + Zanubrutinib Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab Recruiting USA 0
NCT05665062 Phase I Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Recruiting USA 0
NCT05665530 Phase I PRT2527 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies Recruiting USA | ITA | FRA | DEU | CAN | AUS 3
NCT05677919 Phase II Pirtobrutinib + Venetoclax Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia, MIRACLE Study Recruiting USA 0
NCT05694312 Phase II Ibrutinib Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL Recruiting ITA 0
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT05718869 Phase II Tafasitamab-cxix + Zanubrutinib Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study Recruiting USA 0
NCT05753501 Phase I ABBV-101 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Recruiting USA 2
NCT05780034 Phase I AC0676 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies Recruiting USA 0
NCT05797233 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Recruiting USA 0
NCT05878184 Phase I Cyclophosphamide + Fludarabine SC291 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Recruiting USA | AUS 0
NCT05947851 Phase III Rituximab + Venetoclax ARQ 531 + Venetoclax A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 7
NCT05950165 Phase Ib/II CHO-H01 A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma Recruiting USA 1
NCT05963074 Phase II Ibrutinib Ibrutinib + Venetoclax A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) Recruiting USA 0
NCT05963217 Phase I Cyclophosphamide + Fludarabine TBI-2001 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL Recruiting CAN 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT05971251 Phase I Acalabrutinib + Loncastuximab tesirine-lpyl Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia Recruiting USA 0
NCT05983965 Phase I Tazemetostat Acalabrutinib + Tazemetostat Study of Tazemetostat in Lymphoid Malignancies Not yet recruiting USA 0
NCT06136559 Phase III Ibrutinib ARQ 531 Acalabrutinib A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) Recruiting USA | GBR 3
NCT06191887 Phase I Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Recruiting USA 0
NCT06205290 Phase III Idelalisib + Rituximab Lisocabtagene maraleucel Cyclophosphamide + Fludarabine Bendamustine + Rituximab A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies Not yet recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT 2